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Primary revision of mid-vein stenoses in venous
bypass conduits: Venous patch versus
interposition vein
Paul Kreienberg, MD, Mohiuddin Cheema, MD, Benjamin B. Chang, MD, Philip S. K. Paty, MD,
Sean P. Roddy, MD, and R. Clement Darling, III, MD, Albany, NY
Purpose: Patients after infrainguinal vein bypasses are a group at risk of graft stenosis and occlusion. Revision of failing
grafts has been shown to significantly improve bypass patency and limb salvage. Options for surgical revision of mid
bypass stenosis includes either patch angioplasty (PA) or interposition grafting (IG). We reviewed our experience with
surgical revision of vein bypass stenosis.
Methods: From April 1968 toMarch 2006, 7557 autogenous vein bypasses were performed at AlbanyMedical Center and
its affiliated institutions, of these 316 required single or multiple revision of vein grafts with patch angioplasty or
interposition vein grafting. Excluded were proximal and distal anastomotic revisions. Only 235 bypasses had single
revisions as either patch angioplasty (n  108) or interposition grafting (n  127) and are the focus of this review. The
initial bypass revisions in these two groups are analyzed for indications, clinical parameters, operative strategies, and
long-term patencies and clinical outcomes.
Results: There were no significant differences in mean age, gender, or frequency of comorbid conditions (coronary artery
disease, pulmonary disease, hypertension, and diabetes) between the two patient groups. Secondary patency of patch
angioplasty revision at 5 years was 79%. Patencies for interposition grafting revision at 5 years were equivalent to patch
angioplasty group at 75%. When bypasses were evaluated on the basis of initial reconstructions (ie, in situ vs excised vein
bypass), the results showed that in situ bypasses that required initial revision had similar 5-year patencies when
interposition grafting was used as the first revision strategy vs patch angioplasty (80% vs 73%). Excised vein bypasses had
similar patency when patch was their first revision strategy vs interposition grafting (4 year secondary patency 92% vs 75%
respectively).
Conclusion: Autogenous vein bypasses are at risk for developing significant stenosis and occlusion with time. Bypass
stenosis that develops in the main body of the graft can be effectively repaired using either patch angioplasty or
interposition grafting. Depending on the host of other factors, such as availability of autogenous venous conduit, location
of stenosis, accessibility for operative repair, and the patient’s anatomic characteristics, either operative strategy is
effective in prolonging the patency of the bypass. ( J Vasc Surg 2007;45:929-35.)Infrainguinal vein bypass is a well-established therapeu-
tic option in patients with critical limb ischemia and clau-
dication. The use of autogenous vein as a bypass conduit
has been associated with improved patency results com-
pared with prosthetic conduits.1-3 A significant number,
however, will require operative revision to maintain graft
patency. Approximately 20% to 30% of lower extremity vein
grafts require revision to maintain patency in long-term
follow-up.4-6 An aggressive strategy of bypass surveillance
with duplex ultrasound imaging is recommended as a
means of identifying grafts at risk for developing steno-
ses.7,8 Once the failing vein graft is identified by these
hemodynamic criteria, one must decide the best procedural
strategy to maintain bypass patency.
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doi:10.1016/j.jvs.2007.01.018Numerous centers have reported their experiences with
long-term outcomes of revised lower extremity bypass
grafts.9-12 The options for revision of bypass graft stenosis
depends on the etiology and location of the lesion threat-
ening bypass patency. Options include surgical and endo-
vascular interventions. Surgical revisions have traditionally
enjoyed longer patency then their endovascular counter-
parts.13,14 Surgical revision options include patch angio-
plasty, interposition grafting, sequential or jump grafting,
excision, and primary repair.
The techniques most commonly used for the main
body of the vein bypass include patch angioplasty or inter-
position grafting using other available autogenous veins. A
paucity of data exists on the efficacy of vein patch vs
interposition vein grafting in managing the failing vein
bypass.14 This study reviewed our experience with 235 vein
bypasses that were revised for the first time using vein patch
or interposition vein grafting.
METHODS
From April 1968 to March of 2006, 7557 autogenous
vein bypasses were performed at our institution. Of these,
4689 were in situ reconstructions, 2003 were excised vein
bypasses (reversed or orthograde), and 865 were splice vein
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surveillance using clinical examination, pulse volume re-
cordings (PVRs), and duplex ultrasound imaging every 3
months for the first year then every 6 six months there-
after. Bypasses with smaller veins (3 mm), spliced
veins, or partial in situ veins were considered high risk
and were monitored every 2 months during the first year
after surgery. In general, our duplex criteria for revision
are peak systolic velocity  300 cm/s and a PVR 3.5.
A total of 316 bypasses required single or multiple
revisions using patch angioplasty or interposition grafting.
Of these, only 235 bypasses were identified that represented a
single, first time revision as either patch angioplasty (n 108)
or interpositiongrafting (n127).All bypasseswere patent at
the time of revision (ie, none underwent lysis or surgical
thrombectomy) and are the subject of this study. Excluded
from the analysis were the other 81 bypasses that required
simultaneous revision at two different locations, multiple re-
visions at the same location or different location of the bypass,
inflow or outflow revisions, or primary repair (Table I).
The subjects for this study were the patients who had a
Table I. Total vein bypass revisions performed during the
In situ
n (%)
Total 4689
Multiple revisions
5 0 (0)
4 7 (0.1)
3 35 (0.7)
2 138 (2.9)
1 467 (10.0)
0 4042 (86.2) 1
Inflow revisions
Total 83 (1.8)
Direct repairs 9 (0.2)
Interposition 63 (1.3)
Patch 11 (0.2)
Outflow revisions
Total 137 (2.9)
Direct repairs 4 (0.1)
Interposition 131 (2.8)
Patch 2 (0.0)
Proximal vein revisions
Total 91 (1.9)
Direct repairs 7 (0.1)
Interposition 51 (1.1)
Patch 33 (0.7)
Mid-vein revisions
Total 105 (2.2)
Direct repairs 5 (0.1)
Interposition 59 (1.3)
Patch 41 (0.9)
Distal vein revisions
Total 110 (2.3)
Direct repair 3 (0.1)
Interposition 62 (1.3)
Patch 45 (1.0)
Valve lysis 84 (1.8)
Angioplasty 3 (0.1)
Lytic therapy 7 (0.1)first revision patch or interposition in the proximal, mid, ordistal vein position. The decision to perform vein patch or
vein interposition was at the surgeon’s discretion. Short,
focal lesions were treated primarily with patch, whereas
more diffuse lesions were treated with interposition bypass.
Preoperative angiograms were routine except when contra-
indicated because of renal or allergic issues or not deemed
necessary by the operating surgeon.
Available autogenous conduits used for revision were
mapped preoperatively with duplex ultrasound. All patients
received systemic anticoagulation intraoperatively if not
contraindicated. The stenoses were marked by duplex ul-
trasound imaging preoperatively and then confirmed intra-
operatively with hand-held Doppler. Angiography was per-
formed selectively. If the lesions appeared focal (2 cm),
angiography was not performed and the ultrasound find-
ings were used to treat the lesions. Longer lesions and veins
of smaller caliber (2.5 cm) were further evaluated with
contrast angiography.
After proximal and distal control, longitudinal venot-
omy was performed over the area of concern. The proximal
and distal bypass was filled with dextran solution mixed
y period (1968-2006)
rsed
%)
Orthograde excised,
n (%)
Spliced
n (%)
93 210 865
0.2) 0 (0.0) 2 (0.2)
0.0) 0 (0.0) 4 (0.5)
0.2) 1 (0.5) 8 (0.9)
2.0) 2 (1.0) 47 (5.4)
7.1) 11 (5.2) 113 (13.1)
90.5) 196 (93.3) 691 (79.9)
2.2) 2 (1.0) 4 (0.5)
0.3) 0 (0.0) 0 (0.0)
1.5) 2 (1.0) 4 (0.5)
0.5) 0 (0.0) 0 (0.0)
1.6) 3 (1.4) 6 (0.7)
0.1) 1 (0.5) 0 (0.0)
1.4) 2 (1.0) 5 (0.6)
0.1) 0 (0.0) 1 (0.1)
2.4) 2 (1.0) 12 (1.4)
0.2) 1 (0.5) 3 (0.3)
1.3) 1 (0.5) 4 (0.5)
0.9) 0 (0.0) 5 (0.6)
2.8) 3 (1.4) 22 (2.5)
0.3) 0 (0.0) 2 (0.2)
1.5) 3 (1.4) 16 (1.8)
1.0) 0 (0.0) 4 (0.5)
1.6) 3 (1.4) 14 (1.6)
0.1) 0 (0.0) 1 (0.1)
1.1) 2 (1.0) 8 (0.9)
0.4) 1 (0.5) 5 (0.6)
0.3) 1 (0.5) 5 (0.6)
0.1) 0 (0.0) 2 (0.2)
0.2) 1 (0.5) 5 (0.6)stud
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interposition.
Selection of procedure was dependent on the length of
stenosis, availability of conduit, preference of the vascular
surgeon, and exposure of the bypass area involved. In
general, short focal stenoses (ie, retained valve or venoven-
ostomy) were repaired using patch angioplasty, and long
diffuse areas of stenosis (intrinsic vein abnormalities) were
repaired using interposition grafting. The decision of which
technique to use was based upon the length of the lesion. If
the surgeon judged that the total suture line length would
be greater for a patch than for end-to-end anastomosis, the
interposition would be selected.
The technique used for interposition vein revision is
similar to what we have done when performing splice vein
bypass.15 Venovenostomy was performed end to end with
8.0 polypropylene sutures. The ends of the bypass and the
vein being interposed are spatulated to avoid purse string-
ing the anastomosis. All wounds were closed with nonab-
sorbable sutures and staples.
All patients were admitted after surgery, and PVRs and
duplex imaging were performed before discharge. After
revision, patients were followed up for surgical complica-
tions and underwent periodic surveillance every 3 months
or more frequently with duplex ultrasound imaging and
PVRs.
Data on patients undergoing peripheral bypasses were
maintained in a vascular registry for retrospective review.
Information on patient demographics, comorbidities, indi-
cation and type of original bypass, and postoperative com-
plications were recorded on all patients.
Statistical analysis. Differences between groups were
compared using the 2 test for categoric data. The life-table
method was used to determine patency after the first graft
revision. Data are presented in accordance with published
reporting standards.16 The log-rank test was used to ana-
lyze differences. P  .05 was considered significant.
RESULTS
From April 1968 to March of 2006, 235 bypasses
underwent a first revision for bypass stenosis with either
patch angioplasty (n  108) or interposition grafting (n 
127). Of the 108 patch angioplasty procedures, 64 (64%)
were done on in situ bypasses, 19 (20%) on excised, and 25
(26%) spliced vein bypasses. Of the 127 interposition graft
procedures, 62 (50%) were performed on in situ bypasses,
33 (25%) on spliced, and 32 (25%) on excised vein bypasses.
There was no significant difference in mean age (69 years vs
68 years, P  NS) or gender, or in the frequency of
coronary disease, hypertension, pulmonary disease, diabe-
tes, renal insufficiency, or smoking (Table II). Operative
indication is given in Table III.
No operative mortality was encountered in either
group. The major morbidity from these revisions was
wound infections and swelling, which were equally preva-
lent in both groups (20% vs 15%, PNS). The rate for limb
loss at 5 years was 6.4% for vein patch and 3.1% for
interposition repair. The overall patient survival at 5 yearswas 70% for the vein patch group vs 76%, and at 10 years
was 46% for patch angioplasty and 35% for the interposition
group (P  NS).
Secondary patency rates for patch angioplasty and in-
terposition after revision were similar (79% vs 75%, PNS;
Table IV). These patency data represent the patency of the
entire conduit after this initial revision. Restenosis within
the patch or interposition after initial revision was 8% for
patch and 9% for interposition.
When stratified according to the initial bypass proce-
dures, in situ bypasses repaired with interposition grafting
had equivalent 5-year patency (80%) vs patch angioplasty
repair (73%, P  NS; Table V). The excised vein bypasses
demonstrated better patency with patch than interposition
grafting (92% vs 75%) but did not reach statistical signifi-
cance (Table VI). Revised spliced vein bypasses repaired
with patch had a patency of 81% at 2 years compared with
78% for those revised with interposition bypass (Table VII).
DISCUSSION
A significant number of lower extremity vein bypasses
may require revision during their life span. Repair of these
failing bypasses is paramount, as rescuing thrombosed vein
grafts does not generally result in a durable solution.17,18 In
addition, replacement of the failed bypass with new by-
Table II. Demographic data on patients undergoing
either vein patch angioplasty or interposition vein bypass
revision*
Interposition, n (%) Patch, n (%)
Age, mean years 69 68
Males 78 (61) 72 (67)
Smokers 49 (39) 39 (36)
Diabetes mellitus 75 (59) 48 (44)
Coronary artery disease 24 (60) 24 (80)
Hypertension 26 (65) 23 (74)
COPD 6 (15) 4 (13)
Renal 7 (17) 6 (20)
Cholesterol 16 (40) 20 (30)
COPD, Chronic obstructive pulmonary disease.
Student’s t test for age data; 2 analysis for all other data.
P values significant  .05; data for all values was not significant.
Table III. Original bypass indication in patients
undergoing vein patch angioplasty or interposition vein
bypass revision*
Interposition, n (%) Patch, n (%)
Claudication 10 (9) 8 (7)
Gangrene 25 (20) 20 (19)
NHU 51 (40) 48 (44)
Rest pain 35 (27) 31 (29)
Others 6 (4) 1 (1)
Total 127 (100) 108 (100)
NHU, Non-healing ulcer.
*All data analyzed by 2. P was significant at  .05; all data not significant.passes, beyond being a challenge to the surgeon, are gen-
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pass.19-21 Routine surveillance of vein bypasses with
physical examination, PVRs, and duplex ultrasound imag-
ing has therefore become the routine to maintain the
durability of the venous conduit. The duplex examination is
highly specific for identifying lesions that may cause hemo-
dynamic alterations detrimental to long-term patency.
The report of this previous experience was to compare
long-term patency of vein bypasses that had been revised
with those that never required revision. This was different
than our present series because it comprised all revisions,
including valve lysis, fistula ligation, and anastomotic revi-
sions. The focus of our present series is on primarymid-vein
Table IV. Overall patency after first revision for all
bypasses using vein patch or venous interposition
Interposition (all bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 127 14 33 87 4
1-2 80 3 19 84 5
2-3 58 1 15 82 6
3-4 42 3 12 75 8
4-5 27 0 5 75 9
5-6 22 0 9 75 11
Patch (all bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 108 13 22 87 4
1-2 73 4 14 81 5
2-3 55 0 13 81 6
3-4 42 0 9 81 6
4-5 33 1 7 79 8
5-6 25 0 3 79 8
SE, Standard error.
Table V. Patency rate after first revision with either vein
patch or vein interposition in in situ vein bypasses
Interposition (in situ bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 62 7 18 87 0
1-2 37 1 9 84 5
2-3 27 0 5 84 7
3-4 22 1 7 80 7
4-5 14 0 2 80 8
5-6 12 0 5 80 9
Patch (in situ bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 64 10 11 83 0
1-2 43 3 8 76 6
2-3 32 0 5 76 7
3-4 27 0 3 76 8
4-5 24 1 3 73 10
5-6 20 0 1 73 12
SE, Standard error.lesions in conduits undergoing their first revision.When these lesions are identified, the surgeon must
decide what procedure to perform to revise the lesion.
Surgical options include primary repair, vein patch, inter-
position vein bypass, or jump bypass for inflow and outflow
lesions. Lesions in the mid graft are amenable to primary
repair, balloon angioplasty, vein patch, prosthetic patch, or
interposition vein. Of the surgical options, primary repair is
not possible when the lesion is longer and the vein not
redundant enough. We have not used prosthetic patch
(Dacron, polytetrafluoroethylene, or bovine pericardium)
for these mid-vein lesions. Our experience with prosthetic
patch is limited to repair of proximal anastomotic stenosis.
In our experience to date, we have been able to find
adequate vein for revision of these mid-vein stenoses in
either patch or interposition configuration.
Data exist on the efficacy of vein patch and vein inter-
Table VI. Patency rate after first revision with either vein
patch or vein interposition in excised vein bypasses
Interposition (excised vein bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 52 6 11 87 6
1-2 35 2 10 81 8
2-3 23 0 8 81 10
3-4 15 1 4 75 13
4-5 10 0 3 75 15
5-6 7 0 2 75 18
Patch (excised vein bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 33 1 10 96 4
1-2 22 1 4 92 6
2-3 17 0 5 92 8
3-4 12 0 5 92 10
4-5 7 0 3 92 13
5-6 4 0 2 92 19
SE, Standard error.
Table VII. Patency after first revision with either vein
patch or interposition vein in spliced vein bypasses
Interposition (splice vein bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 13 1 4 91 10
1-2 8 1 2 78 17
2-3 5 1 1 61 27
3-4 3 0 2 61 54
Patch (splice vein bypasses)
Year Total Occluded, n Censored, n Patency, % SE, %
0-1 11 2 1 81 12
1-2 8 0 2 81 14
2-3 6 0 3 81 20
3-4 3 0 1 81 25
SE, Standard errorposition in the revision of vein bypasses. Sullivan et al14
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11 repaired with vein interposition.14 They demonstrated
patency of 80% for vein patch and 70% for interposition
vein at 4 years. Their philosophy for vein graft revision was
generally to correct short focal lesions with patch and more
diffuse lesions with vein interposition, thus favoring an
approach that preserves as much conduit as possible with-
out compromising the quality of the revision. They con-
cluded vein path compared with interposition demon-
strated no significant difference in patency. Although the
graft lesions treated with patch were more focal and the
lesions treated with interposition were longer, either tech-
nique represented a durable solution.
Others have demonstrated that vein patch results in a
higher rate of restenosis than interposition grafting. Ban-
dyk et al9 reported a 21% restenosis rate in vein patches and
concluded that interposition repair may be a more durable
solution. However, it is of note that it represented only 31
vein patches in their reported series, and 15 of these were
place at juxta-anastomotic sites.
Nguyen et al21 reviewed the revisions performed at
their institution and observed similar patencies with either
technique.21 Patencies at 5 years were 83% for vein patch
and 73% for interposition. They found that bypasses re-
paired with vein patch tended to require only a single
revision in follow-up.
These results are all consistent with the findings in our
current series that demonstrates equivalent patencies for
either vein patch or vein interposition. The overall resteno-
sis rate at the original site of revision in our series was 8% for
vein patch and 9% for vein interposition.
With the recent advent of endovascular therapies, many
groups have published their data with primary angioplasty
of the vein bypass stenosis. Tong et al22 obtained 3-year
primary assisted patencies of close to 45% using angioplasty
as the first line of treatment, especially for short segment
focal stenoses of 2 cm. Berkowitz et al23 reported their
treatment of mid-graft lesions with balloon angioplasty and
found 5-year patency of 61% for lesions treated by balloon
angioplasty. Avino et al24 reported a 2-year patency rate of
63% for lesions treated by balloon angioplasty and con-
cluded that the use of duplex criteria was critical for a
successful outcome. This includes the treatment of focal
lesions in good caliber vein conduits beyond the early
postoperative period.
Sanchez et al25 reported a 2-year graft patency of 66%
after vein graft percutaneous transluminal angioplasty when
arteriography identified a concentric, short (15 mm)
stenosis in an otherwise normal vein bypass and treatment
resulted in normal appearance of the lesion after the proce-
dure. Poor results were obtained in the treatment of more
complex lesions, including multiple stenoses, recurrent le-
sions, or small diameter vein.
So far, no randomized trials have evaluated angioplasty
vs surgical bypass revision as the twomainmodalities. More
recently, other endovascular strategies such as cutting bal-
loons and cryoplasty have been suggested as potential avail-
able endovascular options to treat these lesions. At present,our group has limited experience with balloon angioplasty
of vein bypass lesions. Given that surgical revision of these
lesions carries nomortality and represents a relatively minor
procedure with durable results, it is hard to deem it neces-
sary to extend endovascular techniques to repair these
lesions. Endovascular treatment may be of value in situa-
tions where anatomic circumstances (anatomically tun-
neled bypass), no autogenous conduit for repair, or severe
comorbid patient condition preclude a more invasive re-
pair.
Although ours is one of the largest reported series, it
represents a single institution experience with the two
revision techniques. It is a retrospective comparison of the
two options. It should be emphasized that this does not
represent a prospective randomized trial of these two tech-
niques; therefore, certain selection bias may exist. It is
possible that stenoses treated with interposition were more
disadvantaged conduits, with longer stenoses not easily
amenable to vein patch.
CONCLUSIONS
Patch angioplasty and vein interposition carry no mor-
tality, afford excellent patencies, long-term limb salvage,
and patient survival. Both procedures are equally effective
in revising in situ, excised vein, or spliced vein bypasses. The
selection of procedure should depend on location and
length of lesion, available conduit, and patient comorbidi-
ties.
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Dr Daniel B. Walsh (Lebanon, NY). This paper’s critical
finding is that vein patch angioplasty and vein graft interposition of
mid-vein graft stenoses in situ bypasses achieve similar 5-year
patency results. In a smaller group of excised grafts, the interposi-
tion graft did not fair quite as well.
Are these truly comparable groups? The authors readily admit
that this was not a randomized trial. The individual surgeon
determined the therapeutic strategy. Was it clear that both options
were possible in all these patients, or were there other determining
factors such as vein quality or availability? Clearly, the group with
excised veins had to be different, as these patients did not have vein
available for in situ bypass at the original procedure. Is this the
reason the interposition group did not fair as well? Can the authors
comment on the impact of this potential selection bias on their
results. Since their study, have they changed their practice in any
way when dealing with mid-graft stenoses?
Dr Paul B. Kreienberg. Thank you very much for your
comments. I agree we are limited because this is a retrospective
review and is not randomized. And I think, certainly, the excised
vein group is somewhat disadvantaged as compared to the in situ
group in terms of the quality of the vein.
If you look at the overall revision rate for the different types of
bypasses, it is higher in excised veins. When you break out the
revisions for the in situs that were just fistula ligation or simple
valve lysis, you see the difference. Revision rates on the splices and
the excised veins are actually a little bit higher, and so there is some
selection bias.
Now, the options for repair, both options may not be available
in all patients and that’s where part of the selection problem comes
in. Basically, our algorithm for repairing vein lesions is to do
primary repair first if the lesions are short enough and enough veinthe interposition. Which one of the latter two you choose really
depends on the available conduit.
Now, although it wasn’t statistically significant, the interposi-
tions did have a somewhat poorer patency. I’ll need to explore this
a little deeper and go back and review the patients who had the
excised veins.
We know if bypasses need to be revised earlier in their lifespan,
they’re more likely to require more revisions to maintain patency
and they don’t tend to perform as well. We did take out all the ones
that were revised at less than a month after their initial procedure.
Despite this we still didn’t see any difference in that data.
I just want to touch on, a little bit, the genesis of this paper.
Our group gets together every morning. We stand at the angio-
gram viewer with the fellows, all the surgeons are there, and put up
the cases of the day. And every once in a while a case will come up
where there is a lesion that we’re going to have to revise, and
there’s four of us that say we should fix that with a patch and four
of us say we should fix this with an interposition.
I know when I first started in practice, I was kind of loathe to
put a patch over this rubbery, hypertrophied, eccentric lesion and
say it is going to function as well. And I think by going back and
looking at our data, I feel, I have a little more peace of mind when
I place a patch over that area.
Dr Ronald L. Nath (Stoneham, MA). We tend to use bovine
pericardium as our conduit of choice either for veins grafts, other
types of grafts, or arteries that need patching. I wonder if you have
had experience with bovine pericardium and therefore why you
have chosen to harvest a piece of vein primarily rather than saving
vein for conduit use.
A second question I would like to ask may not strictly relate to
the paper. We have always been taught that use of spliced vein for
bypass conduit has a much lower patency rate, as you yourself have
shown here, because of the number of anastomoses required, that
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that particular conduit. If that is true, then one would think that a
patch would fare better than a spliced vein bypass repair. Does that
logic follow? Have you been able to analyze that subset?
Dr Kreienberg. Well, to answer the last question first, Dr
Chang from our group published a paper on spliced veins and
found that the patency really didn’t change until you got beyond
four splices. So with one interposition in there, it is not going to
make a difference.
As to the bovine pericardial patch, my only experience with
that is doing patches for inflow lesions, and I have not used it on
the conduit itself.
Usually, if you are performing a patch, you can find a segment
of vein somewhere. And basically, the order we go through for
looking for vein is probably to use residual greater from the
ipsilateral leg, see if there is residual greater from the contralateral
leg, then we use lesser, or arm vein, in that order. Usually for a vein
patch, you can find even a branch that you can use that will be long
enough to perform the patch, such as the descending lateral branch
of the saphenous vein.
Dr Steven P. Rivers (Bronx, NY). I’d also like to explore a
little bit where you are getting the source of your conduits,
specifically for the interposition grafts. Are they primarily con-
tralateral greater saphenous, ipsilateral lesser saphenous, cephalic?
Do you have enough of each that you can say with any confidence
that the vein from one location functions better than a vein from
another location?If you have a failing bypass graft in one leg and a patient with
contralateral disease, I mean, I guess the real question is should we
use the ipsilateral lesser saphenous and save the other side, or
should we take the best vein, which is the greater saphenous, from
the other leg?
Dr Kreienberg. The choice becomes important. I don’t have
the data for exactly what distribution of the interpositions were in
terms of using arm vein, lesser saphenous vein or greater saphenous
vein. Obviously, you do have to keep in mind when you are
performing that, you want to put in the best piece you can but
preserve further options down the road.
Dr William R. Flinn (Baltimore, MD). Dr Kreinenberg, do
you ever not operate on these? Do you ever do angioplasties on any
of them? Is there any indication for this or other endovascular
interventions for vein graft stenoses?
Dr Kreienberg. There are some patients that—and I have a
couple patients that I follow—have basically got increased
velocities in a segment due to comorbidities. I followed some of
them and let them drift a little higher before I would operate on
them.
In the reverse veins, and in the spliced veins, we tunnel
everything subcutaneously. So the access to these is relatively easy.
So even in a patient who has maybe severe comorbid problems, this
is a procedure that can be done under local anesthesia. And so there
are very few patients who develop a lesion that we won’t operate
on.
